Correction: The new type of COVID-19 treatment being offered at UPMC Hamot is for immunocompromised patients. The article has been corrected. We apologize for the error.
UPMC Hamot staff are now administering the first ever monoclonal antibody cocktail authorized by the FDA for the prevention of COVID-19 prior to exposure called Evusheld.
The Director of Operations at UPMC Hamot says they are offering this treatment to select immunocompromised patients. He says UPMC Hamot will likely receive about 50 antibody injections a week.
“We have five sites throughout the system that are ready to give these and it’s an honor to be able to give these to our patients that are at the most risk. Ultimately, the goal is to prevent people from hospitalization and this is a huge benefit to those patients, just extra protection for them from COVID.” said Daniel Gessel, Director of Operations at UPMC Hamot.
For news delivered right to you, subscribe to JET 24/FOX 66/YourErie.com’s breaking, daily news & severe weather email lists
Qualifying patients will be contacted by UPMC Hamot. There is no call in line at this time.